Literature DB >> 21291342

Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly.

Hilal Ozkan1, Merih Cetinkaya, Nilgün Köksal, Senay Yapici.   

Abstract

Valproic acid (VPA) is a teratogenic drug used in pregnant women for the treatment of epilepsy and mood disorders. Fetal valproate syndrome (FVS) is characterized by a number of abnormalities associated with VPA exposure in utero including neural tube defects, congenital heart defects, limb defects, genitourinary defects, brain, eye and respiratory anomalies, and abdominal wall defects. Complex cardiac defect and trigonocephaly have rarely been reported and multicystic dysplastic kidney has never been detected in FVS. We here report a female infant who was born to a mother with a history of low-dose VPA monotherapy (250 mg/day) during pregnancy and who had presented with a combination of unilateral multicystic dysplastic kidney, multicomplex cardiac defect including severe coarctation of aorta, Ebstein anomaly, secundum atrial septal defect, mesocardia along with trigonocephaly due to metopic craniosynostosis, typical facial appearance and limb defects. To our knowledge, this is the first case presented with multicystic dysplastic kidney, complex cardiac defect, trigonocephaly and other limb and facial defects because of exposure to very low-dose VPA monotherapy (250 mg/day) in utero. We conclude that VPA must be used very cautiously in pregnant women even as monotherapy and in low doses to prevent major congenital defects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291342     DOI: 10.3109/14767058.2010.501120

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  6 in total

1.  Valproate fetopathy.

Authors:  K M Sargar; T E Herman; M J Siegel
Journal:  J Perinatol       Date:  2015-01       Impact factor: 2.521

Review 2.  Environmental aspects of congenital scoliosis.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Environ Sci Pollut Res Int       Date:  2015-01-29       Impact factor: 4.223

Review 3.  Bipolar Disorder in Pregnancy and Postpartum: Principles of Management.

Authors:  Sabrina J Khan; Madeleine E Fersh; Carrie Ernst; Kim Klipstein; Elizabeth Streicker Albertini; Shari I Lusskin
Journal:  Curr Psychiatry Rep       Date:  2016-02       Impact factor: 5.285

4.  Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay.

Authors:  Marilena Colaianna; Sten Ilmjärv; Hedi Peterson; Ilse Kern; Stephanie Julien; Mathurin Baquié; Giorgia Pallocca; Sieto Bosgra; Agapios Sachinidis; Jan G Hengstler; Marcel Leist; Karl-Heinz Krause
Journal:  Arch Toxicol       Date:  2016-03-25       Impact factor: 5.153

5.  Diagnosis and management of individuals with Fetal Valproate Spectrum Disorder; a consensus statement from the European Reference Network for Congenital Malformations and Intellectual Disability.

Authors:  Jill Clayton-Smith; Rebecca Bromley; John Dean; Hubert Journel; Sylvie Odent; Amanda Wood; Janet Williams; Verna Cuthbert; Latha Hackett; Neelo Aslam; Heli Malm; Gregory James; Lena Westbom; Ruth Day; Edmund Ladusans; Adam Jackson; Iain Bruce; Robert Walker; Sangeet Sidhu; Catrina Dyer; Jane Ashworth; Daniel Hindley; Gemma Arca Diaz; Myfanwy Rawson; Peter Turnpenny
Journal:  Orphanet J Rare Dis       Date:  2019-07-19       Impact factor: 4.123

Review 6.  Chromatin Imbalance as the Vertex Between Fetal Valproate Syndrome and Chromatinopathies.

Authors:  Chiara Parodi; Elisabetta Di Fede; Angela Peron; Ilaria Viganò; Paolo Grazioli; Silvia Castiglioni; Richard H Finnell; Cristina Gervasini; Aglaia Vignoli; Valentina Massa
Journal:  Front Cell Dev Biol       Date:  2021-04-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.